Ironstomach

Phase 4

Not yet recruiting

• Conditions: Patients with gastric cancer

• Registration Number: 2024-519738-21-01
• Lead Sponsor: HUS-Yhtymae

Brief Summary

TO investigate if preoperative iron infusion decreases the risk of transfusions and complications in after operation for gastric cancer.

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-12-16
• Last Update Posted: 2024-12-16

Recruitment & Eligibility

• Status: Authorised, recruitment pending
• Sex: Not specified
• Target Recruitment: 202

Inclusion Criteria

Adult patients with gastric cancer

Exclusion Criteria

Patients under 18 years old Patients not in full understanding Hemoglobin levels > 155 g/l for women and >167 g/l for men (upper reference limits for the laboratory of Helsinki University Hospital district) preoperatively. Transferrin saturation level >50% Emergency gastrectomy Palliative gastrectomy Acute bacterial infection Known hypersensitivity to the active substance, to ferric carboxymaltose or any of its excipients, or to other parental iron products Clinical evidence of iron overload or disturbances in the utilisation of iron Patients <35 kg Dialysis therapy for chronic renal failure Hemochromatosis Polycytemia vera Pregnancy Patients in need of direct blood transfusion

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of patients receiving transfusions		Number of patients receiving transfusions

Secondary Outcome Measures

Name	Time	Method
Postoperative Hb level, complications and quality of life		Postoperative Hb level, complications and quality of life

Trial Locations

Locations (1)

HUS-Yhtymae; 🇫🇮 Helsinki, Finland

HUS-Yhtymae

🇫🇮Helsinki, Finland

Arto Kokkola

Site contact

+358504271048

arto.kokkola@hus.fi